PITTSBURGH (AP) – Mylan has agreed to pay $30 million in a settlement tied to its failure to tell investors about a Justice Department investigation into whether the company overcharged Medicaid for the EpiPen. The Securities and Exchange Commission said today that Mylan NV classified the EpiPen as a “generic” drug under the Medicaid drug rebate program. This led to the pharmaceutical company paying much lower rebates to the government than if the EpiPen had been classified as a “branded” drug. Mylan disclosed in July that it had reached an agreement-in-principle with the SEC on the matter. The company said in their statement today that it neither admits nor denies the SEC’s allegations.